• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

tetano

Editor, Senior Moderator
Nat Commun


. 2024 Dec 30;15(1):10764.
doi: 10.1038/s41467-024-54458-w. Antibodies to the RBD of SARS-CoV-2 spike mediate productive infection of primary human macrophages

Suzanne Pickering[SUP] 1 [/SUP], Harry Wilson[SUP] 2 [/SUP], Enrico Bravo[SUP] 2 [/SUP], Marianne R Perera[SUP] 2 [/SUP], Jeffrey Seow[SUP] 2 [/SUP], Carl Graham[SUP] 2 [/SUP], Nathalia Almeida[SUP] 2 [/SUP], Lazaros Fotopoulos[SUP] 3 4 [/SUP], Thomas Williams[SUP] 3 4 [/SUP], Atlanta Moitra[SUP] 2 [/SUP], Helena Winstone[SUP] 2 [/SUP], Tinne A D Nissen[SUP] 2 5 [/SUP], Rui Pedro Galão[SUP] 2 [/SUP], Luke B Snell[SUP] 2 6 [/SUP], Katie J Doores[SUP] 2 [/SUP], Michael H Malim[SUP] 2 [/SUP], Stuart J D Neil[SUP] 2 [/SUP]



Affiliations
Abstract

The role of myeloid cells in the pathogenesis of SARS-CoV-2 is well established, in particular as drivers of cytokine production and systemic inflammation characteristic of severe COVID-19. However, the potential for myeloid cells to act as bona fide targets of productive SARS-CoV-2 infection, and the specifics of entry, remain unclear. Using a panel of anti-SARS-CoV-2 monoclonal antibodies (mAbs) we performed a detailed assessment of antibody-mediated infection of monocytes/macrophages. mAbs with the most consistent potential to mediate infection were those targeting a conserved region of the receptor binding domain (RBD; group 1/class 4). Infection was closely related to the neutralising concentration of the mAbs, with peak infection occurring below the IC50, while pre-treating cells with remdesivir or FcγRI-blocking antibodies inhibited infection. Studies performed in primary macrophages demonstrated high-level and productive infection, with infected macrophages appearing multinucleated and syncytial. Infection was not seen in the absence of antibody with the same quantity of virus. Addition of ruxolitinib significantly increased infection, indicating restraint of infection through innate immune mechanisms rather than entry. High-level production of pro-inflammatory cytokines directly correlated with macrophage infection levels. We hypothesise that infection via antibody-FcR interactions could contribute to pathogenesis in primary infection, systemic virus spread or persistent infection.


 
Back
Top Bottom